MA63885B1 - Compounds that inhibit the alpha isoform of PI3K and methods of treating cancer - Google Patents
Compounds that inhibit the alpha isoform of PI3K and methods of treating cancerInfo
- Publication number
- MA63885B1 MA63885B1 MA63885A MA63885A MA63885B1 MA 63885 B1 MA63885 B1 MA 63885B1 MA 63885 A MA63885 A MA 63885A MA 63885 A MA63885 A MA 63885A MA 63885 B1 MA63885 B1 MA 63885B1
- Authority
- MA
- Morocco
- Prior art keywords
- pi3k
- methods
- inhibit
- compounds
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231156P | 2021-08-09 | 2021-08-09 | |
| PCT/US2022/039674 WO2023018636A1 (en) | 2021-08-09 | 2022-08-08 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA63885A1 MA63885A1 (en) | 2024-09-30 |
| MA63885B1 true MA63885B1 (en) | 2025-01-31 |
Family
ID=83188497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63885A MA63885B1 (en) | 2021-08-09 | 2022-08-08 | Compounds that inhibit the alpha isoform of PI3K and methods of treating cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240343728A1 (en) |
| EP (1) | EP4363414A1 (en) |
| JP (1) | JP2024533975A (en) |
| KR (1) | KR20240051953A (en) |
| CN (1) | CN118159534A (en) |
| AU (1) | AU2022325819A1 (en) |
| CA (1) | CA3227902A1 (en) |
| CL (1) | CL2024000327A1 (en) |
| CO (1) | CO2024000448A2 (en) |
| CR (1) | CR20240045A (en) |
| DO (1) | DOP2024000019A (en) |
| EC (1) | ECSP24008488A (en) |
| IL (1) | IL310588A (en) |
| MA (1) | MA63885B1 (en) |
| MX (1) | MX2024000708A (en) |
| PE (1) | PE20240652A1 (en) |
| WO (1) | WO2023018636A1 (en) |
| ZA (1) | ZA202401094B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4611741A1 (en) | 2022-11-02 | 2025-09-10 | Petra Pharma Corporation | Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
| WO2025036439A1 (en) * | 2023-08-16 | 2025-02-20 | Laekna Pharmaceutical Ningbo Co., Ltd. | Multicyclic compounds and their use as pi3k alpha inhibitors |
| WO2025144931A1 (en) * | 2023-12-27 | 2025-07-03 | Genesis Therapeutics, Inc. | Methods for treating cancer |
| WO2025201503A1 (en) * | 2024-03-28 | 2025-10-02 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010108074A2 (en) * | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| WO2011035855A1 (en) * | 2009-09-28 | 2011-03-31 | Merck Patent Gmbh | Pyridinyl-imidazolone derivatives for inhibiting pi3 kinases |
| WO2017001645A1 (en) * | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9944639B2 (en) * | 2014-07-04 | 2018-04-17 | Lupin Limited | Quinolizinone derivatives as PI3K inhibitors |
| WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
-
2022
- 2022-08-08 JP JP2024506896A patent/JP2024533975A/en active Pending
- 2022-08-08 CR CR20240045A patent/CR20240045A/en unknown
- 2022-08-08 IL IL310588A patent/IL310588A/en unknown
- 2022-08-08 PE PE2024000156A patent/PE20240652A1/en unknown
- 2022-08-08 EP EP22764505.8A patent/EP4363414A1/en active Pending
- 2022-08-08 CA CA3227902A patent/CA3227902A1/en active Pending
- 2022-08-08 CN CN202280062281.6A patent/CN118159534A/en active Pending
- 2022-08-08 MA MA63885A patent/MA63885B1/en unknown
- 2022-08-08 AU AU2022325819A patent/AU2022325819A1/en active Pending
- 2022-08-08 MX MX2024000708A patent/MX2024000708A/en unknown
- 2022-08-08 US US18/293,823 patent/US20240343728A1/en active Pending
- 2022-08-08 WO PCT/US2022/039674 patent/WO2023018636A1/en not_active Ceased
- 2022-08-08 KR KR1020247007455A patent/KR20240051953A/en active Pending
-
2024
- 2024-01-18 CO CONC2024/0000448A patent/CO2024000448A2/en unknown
- 2024-02-01 EC ECSENADI20248488A patent/ECSP24008488A/en unknown
- 2024-02-02 CL CL2024000327A patent/CL2024000327A1/en unknown
- 2024-02-02 ZA ZA2024/01094A patent/ZA202401094B/en unknown
- 2024-02-02 DO DO2024000019A patent/DOP2024000019A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010108074A2 (en) * | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| WO2011035855A1 (en) * | 2009-09-28 | 2011-03-31 | Merck Patent Gmbh | Pyridinyl-imidazolone derivatives for inhibiting pi3 kinases |
| WO2017001645A1 (en) * | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024000327A1 (en) | 2024-08-09 |
| CN118159534A (en) | 2024-06-07 |
| PE20240652A1 (en) | 2024-04-04 |
| EP4363414A1 (en) | 2024-05-08 |
| US20240343728A1 (en) | 2024-10-17 |
| MA63885A1 (en) | 2024-09-30 |
| CR20240045A (en) | 2024-02-20 |
| CO2024000448A2 (en) | 2024-02-15 |
| ZA202401094B (en) | 2025-05-28 |
| MX2024000708A (en) | 2024-02-08 |
| AU2022325819A1 (en) | 2024-02-29 |
| KR20240051953A (en) | 2024-04-22 |
| CA3227902A1 (en) | 2023-02-16 |
| WO2023018636A1 (en) | 2023-02-16 |
| ECSP24008488A (en) | 2024-05-31 |
| DOP2024000019A (en) | 2024-03-15 |
| JP2024533975A (en) | 2024-09-18 |
| IL310588A (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2023000286A1 (en) | Urea derivatives which can be used to treat cancer | |
| MA63885B1 (en) | Compounds that inhibit the alpha isoform of PI3K and methods of treating cancer | |
| MA52486B1 (en) | Pyridazinones used as parp7 inhibitors | |
| MA34361B1 (en) | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | |
| MA50013B1 (en) | BENZOAZEPINE ANALOGS AS BRUTON'S TYROSINE KINASE INHIBITORS | |
| MA38661A1 (en) | Heteroaromatic compounds and their use as d1 dopamine ligands | |
| MA33450B1 (en) | Oxazin derivatives and used as basic inhibitors for the treatment of neurological disorders | |
| EP2091328A4 (en) | BETA-SECRETASE INHIBITORY SPIROPIPERIDINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| WO2023107723A3 (en) | Cyclic compounds and their use for the treatment of neurological disorders | |
| EA201001821A1 (en) | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | |
| HRP20050533A2 (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
| MA30911B1 (en) | NOVEL SULFONAMIDE DERIVATIVES AS BRADYKININE ANTAGONISTS | |
| MA35285B1 (en) | indazoles | |
| SA523451700B1 (en) | Allosteric Chromenone Inhibitors of Phosphoinositide 3-Kinase (PI3K) for The Treatment of Disease | |
| MA44948A1 (en) | Bace 1 inhibitors | |
| MA40955B1 (en) | 2-amino-6- (difluoromethyl) -5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MX2022012575A (en) | Compounds for treating huntington's disease. | |
| MA41494B1 (en) | Benzoxaborole compounds substituted in position 4 and associated uses | |
| EA202191955A1 (en) | MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS | |
| MX2025004073A (en) | Methods for treating cancer | |
| MX2024007062A (en) | Heterocyclic compounds as dyrk1a inhibitors. | |
| CA3242701A1 (en) | GM2 GANGLIOSIDOSIS TREATMENT | |
| EA200601607A1 (en) | SULPHONAMIDE CONNECTIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| MX2023015408A (en) | TRANSGLUTAMINASE INHIBITORS. | |
| EP2073635A4 (en) | MACROCYCLIC SPIROPIPERIDINE INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE |